Exposure to carcinogens not proportionally decreased by reduction in smoking

January 20, 2004

Smokers who substantially reduce the number of cigarettes they smoke per day are exposed to lower amounts of a potent tobacco carcinogen; however, the reduction in the amount or concentration of the carcinogen exposure is often transient and is not proportional to the reduction in cigarettes smoked. These study results appear in the January 21 issue of the Journal of the National Cancer Institute.

Cigarette smoking is the cause of 90% of the world's lung cancer cases, but it is not known whether smokers who reduce the number of cigarettes smoked per day also decrease their risk of lung cancer.

Stephen S. Hecht, Ph.D., of the University of Minnesota Cancer Center, Minneapolis, and colleagues set out to answer this question by measuring the metabolites of a specific tobacco carcinogen in the urine of smokers who were part of a structured smoking reduction program. The carcinogen, NNK, along with polycyclic aromatic hydrocarbons, are some of the most important tobacco carcinogens with respect to lung cancer.

The people in the study, who overall had smoked an average of 23.7 cigarettes per day, gave two urine samples 1 week apart before reducing their cigarette consumption by 25% for 2 weeks, 50% for another 2 weeks, and then by 75% for the duration of the study. Urine samples were collected at several specific points throughout the 6-month study period to measure levels of the NNK metabolites, called NNAL and NNAL-Gluc. The researchers also measured the level of the compound anatabine to biochemically verify the patients' self reports of cigarette consumption. Patients were offered nicotine replacement therapy to assist their smoking reduction efforts.

Overall, there was a reduction in NNAL and NNAL-Gluc levels at nearly all of the intervals as the 92 patients who completed the study reduced the number of cigarettes smoked each day. However, the magnitude of the reduction was generally less than the reduction in cigarettes smoked per day. For example, smokers who reduced their cigarettes per day by 55% to 90% during weeks 4 through 12 had reductions of only 27% to 51% in total NNAL. Even when smokers reduced their cigarettes per day from a mean of 24.7 at the beginning of the study to 2.60 at week 12 (a reduction of 90%), the average level of total NNAL was only reduced by 46%.

The authors suggest that the most likely explanation for the results is that people who are trying to cut back by smoking fewer cigarettes per day alter their smoking behavior by inhaling longer and deeper, which is known to alter a smoker's exposure to carcinogens. "The results indicate that some smokers may benefit from reduced smoking, but for most the effects are modest, probably due to compensation," the authors conclude.

In a commentary in the same issue of the Journal, Paolo Vineis, M.D., and his colleagues--a team of epidemiologists who participated in a 2002 working group that prepared a monograph on tobacco smoking and secondhand smoking for the International Agency for Research on Cancer (IARC)--review the evidence for a causal relationship between tobacco use and cancers not previously believed to be associated with smoking, such as cancers of the upper aero-digestive tract, stomach, liver, kidney, uterine cervix, and large bowel, and myeloid leukemia. They also summarize the causal association between cancer and tobacco use other than smoking, such as bidi, cigar, and pipe smoking.

"Although 1 billion people worldwide already smoke and more will start, individuals who stop smoking reduce their smoking-related cancer risks effectively," they write. "A balanced public health strategy is therefore needed that not only prevents young individuals from starting to smoke, but also helps adults stop smoking."

In an accompanying editorial, Scott J. Leischow, Ph.D., and Mirjana Djordjevic, Ph.D., of the Tobacco Control Research Branch at the National Cancer Institute, discuss how these two distinct but complementary papers highlight that tobacco's role as a cancer initiator and promoter not only is multifactorial and complex, but also remains one of the greatest global public health challenges. "Given the dearth of evidence supporting the viability and benefits of reduced smoking as a harm reduction strategy, and given the strong evidence that smoking cessation can have a dramatic impact on future tobacco-related morbidity and mortality, the IARC working group correctly concludes that the most dramatic health benefits in the next half century will occur if we can significantly increase the number of smokers who quit," they write.
-end-
Contacts:
  • Hecht et al.: Brenda Hudson, University of Minnesota, 612-624-5680, bhudson@umn.edu
  • Commentary: Nicolas Gaudin, International Agency for Research on Cancer, 33-4-72-73-85-67, gaudin@iarc.fr
  • Editorial: National Cancer Institute, 301-496-6641, ncipressofficers@mail.nih.gov

    Citations:
  • Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, Kramarczuk I, et al. Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 2004;96:107-15.
  • Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004;96:99-106.
  • Leischow SJ, Djordjevic. Smoking reduction and tobacco-related cancers: The more things change, the more they stay the same. J Natl Cancer Inst 2004;96:86-7.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oupjournals.org/.

    Journal of the National Cancer Institute

    Related Cancer Articles from Brightsurf:

    New blood cancer treatment works by selectively interfering with cancer cell signalling
    University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

    UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
    A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

    Breast cancer treatment costs highest among young women with metastic cancer
    In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

    Cancer mortality continues steady decline, driven by progress against lung cancer
    The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

    Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
    Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

    Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
    The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

    Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
    Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

    More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
    An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

    New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
    Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

    American Cancer Society outlines blueprint for cancer control in the 21st century
    The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

    Read More: Cancer News and Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.